Navigation Links
KanekaQH(TM) Ubiquinol Dramatically Boosts Ejection Fraction in Patients With Late-Stage Congestive Heart Failure
Date:2/18/2009

Results of first clinical trial indicate pre-converted form of Coenzyme Q10 positively impacted heart function in critically ill subjects

HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clinical trial evaluating ubiquinol's effects on late-stage congestive heart failure showed that the newly available pre-converted form of Coenzyme Q10 (CoQ10) dramatically boosted ejection fraction in critically ill patients. Published in the January 2009 issue of Biofactors, a peer-reviewed scientific journal, the year-long study showed that patients' ejection fraction (EF), the capacity at which their heart pumps blood, in some cases more than tripled.

Healthy individuals typically have EF levels of 55 to 70 percent. Damage to the heart muscle, such as that sustained following a heart attack, heart-valve problems, or during myocardial infarction or myocardiomyopathy, impairs the heart's ability to eject blood and therefore reduces EF.

All of the patients that participated in this clinical trial had an EF level below a 35 percent and were classified as New York Heart Association (NYHA) Class IV - a designation that denotes patients' showed symptoms of insufficient heart function while at rest and were unable to carry out any form of physical activity without discomfort. The prognosis for patients with NYHA Class IV heart failure is very poor, with mortality rates as high as 74 percent within 6 months and 94 percent within 12 months.

From June 2006 through May of 2007, the clinical trial followed seven Class IV patients who were under maximal medical therapy and supplementing their treatments with ubiquinone (CoQ10). The study, led by cardiologist Peter Langsjoen, assessed the effect of changing their ubiquinone supplementation to ubiquinol (Kaneka QH(TM)).

When switched to supplemental ubiquinol, there was a dramatic increase in both the patients' EF and plasma CoQ10 levels with corresponding improvements in clinical status in all seven patients. The improvements while on ubiquinol were so significant that six of the seven patients survived longer than expected and remained stable between NYHA Class I-III for an average of 12 months.

"In 25 years of experience in treating congestive heart failure, we have consistently seen the best response when CoQ10 is begun early in the course of the disease," said Dr. Langsjoen, who conducted the research in Tyler, Texas.

"The improvement in ejection fraction levels in these seven patients with end-stage congestive heart failure was associated with overall clinical improvement. It is likely that ubiquinol would show even more clinical benefit in early congestive heart failure. Future controlled trials of Kaneka QH(TM) in congestive heart failure are anxiously awaited."

About Kaneka QH(TM) (ubiquinol)

Both ubiquinone and ubiquinol are essential to generating cellular energy and sustaining life; however, the reduced form, ubiquinol, is responsible for the powerful antioxidant benefits associated with CoQ10. More than 90 percent of the CoQ10 found in a healthy person's plasma is in its reduced ubiquinol form.

For the past 40 years, only ubiquinone was available as a supplement. KanekaQH(TM), the world's only supplemental ubiquinol, has only been available since late 2006. The ingredient, manufactured exclusively by Kaneka, is currently available in more than 30 consumer supplements.

"Cardiovascular patients, those fighting age-related diseases and even healthy people over the age of 40 have a critical need to optimize the EF and plasma CoQ10 levels within their bodies," explained Dr. Robert Barry of Kaneka Nutrients, L.P. "Because it's so much better absorbed by the body, KanekaQH(TM) can raise CoQ10 levels more effectively and, as we're seeing from Dr. Langsjoen's study, can have tremendous health impact on those suffering from debilitating diseases."

Full results of Dr. Langsjoen's supplemental ubiquinol study is available www.kanekaqh.com/clinicaltrials. More information on supplemental ubiquinol is available at www.kanekaqh.com.

About Kaneka Nutrients

Kaneka Nutrients L.P. is a wholly-owned subsidiary of Kaneka Corporation (www.kaneka.co.jp/kaneka-e/), headquartered in Japan. The company, based in Pasadena, Texas, manufactures an array of unique nutritional ingredients for the supplement and food & beverage industries. Kaneka is the largest manufacturer of CoQ10 in the world, and the only company that manufactures CoQ10 in the U.S.


'/>"/>
SOURCE Kaneka Nutrients L.P.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NVIDIA CUDA Technology Dramatically Advances the Pace of Scientific Research
2. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
3. DolmatConnell & Partners 2008 Studies of CEO and CFO Compensation in the 100 Largest High Technology and Life Science Companies Show Dramatically Improving Link Between Pay and Performance
4. Elusys Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
5. Winning University of Melbourne Ph.D. research boosts the search for sensitive sensors
6. New Study Finds Growth Factor Boosts Productivity in Mammalian Cell Culture
7. On the boil: New nano technique significantly boosts boiling efficiency
8. Genzyme Boosts Quality Using Dyadem Quality Lifecycle Management
9. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
10. New Scandinavian collaboration boosts nanotech development
11. Murad Boosts Skin Immunity With the New Murad(R) Professional Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. ... mobile health and big data solutions, today announced that ... insurance coverage option for U.S. consumers who want to ... DarioHealth has signed strategic alliance agreements with partners ... insurance coverage benefits, and if approved, will supply and ...
(Date:3/24/2017)... , March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" ... in China , today announced that its board ... expiration date of the plan from March 27, 2017 to March ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
(Date:3/23/2017)... ... ... proud to announce it has become the premiere team-building cooking event company in San Diego. ... such as Illumina, HP and Qualcomm, and is ranked #1 in its category on Trip ... its new team building format, a way for teams to not only interact with one ...
(Date:3/23/2017)... Calif., March 23, 2017  BioPharmX Corporation (NYSE ... for the dermatology market, today reported financial results ... 2017, and will provide an update on the ... year. "We are pleased to report ... for BioPharmX," said President Anja Krammer. "We achieved ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
Breaking Biology News(10 mins):